Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.

Also called NCT03385239

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 114 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03385239
Other papers using this trial's data
  • Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk European heart journal, 2022-04-06 DOI, PubMed 35025993, PMC8986458 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03385239. Randomized; triple masking; primary purpose treatment. Start 2018-01-30 (actual); primary completion 2019-11-25 (actual). Results posted on 2023-01-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
Condition
Hypertriglyceridemia
Condition
Cardiovascular Diseases
Intervention (Drug)
ISIS 678354
Intervention (Drug)
Placebo
Lead sponsor
Akcea Therapeutics (class: industry)
Collaborator
Ionis Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03385239
Content hash
11747eda912ee33b2cd0003dc6b10f87db2da90ac72969a4275ae6b018142bc8